CAR-T cell therapy for large B-cell lymphoma offers a breakthrough option for relapsed or refractory cases, using engineered immune cells to target CD19-positive cancer cells with high remission rates.
A real-world study in China demonstrates that Yorwida CAR-T therapy can improve relapse-free survival in adult B-ALL patients with high-risk genetic features, particularly when used early in CR1-MRD-negative settings.
At ASH 2025, new data reveals that Inaticabtagene Autoleucel delivers high response rates and durable remissions in adult B-ALL patients who relapse after stem cell transplant.
A real-world analysis of inaticabtagene autoleucel in China demonstrates high response and MRD-negative rates, durable remissions, and favorable safety in adult patients with B-cell acute lymphoblastic leukemia, including high-risk and CNS-involved disease.
China approves a second indication for the homegrown CD19 CAR-T therapy Yorwida, bringing new hope to patients with relapsed or refractory large B-cell lymphoma.
CNCT19 (Inaticabtagene Autoleucel) is the China’s first independently developed CAR T-cell therapy in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). On December 3, 2024, the
CNCT19 is the first approved CAR T-cell therapy in China for the treatment of adult B-ALL.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.